The +177% rally in $Moderna is a massive clinical milestone for mRNA tech, but chasing a parabolic move at this level carries significant downside risk.
While long-term growth for oncology mRNA therapies with $Merck looks promising, short-term profit taking and insider selling are real risks after such a huge leap. I’d rather sit this initial surge out and wait for a healthy pullback to build a position safely.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.